VBI Vaccines Inc. Stock News

Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-shortened week. Shares of companies with a COVID portfolio, including a vaccine, a treatment or both, reacted with strong moves to the upside in the truncated session on Friday. Takeda Pharmaceutical Company Limited (NYSE: TAK ) and Aadi Bioscience, Inc. (NASDAQ: AADI ) received Food and Drug Administration nod for their Livtencity and Fyarro, respectively. Here are the catalysts that could impact trading in the upcoming week: Conferences The Evercore ISI 4th Annual HealthCONx Virtual Conference: Nov. 30-Dec. 2 Piper Sandler 33rd Annual Virtual Healthcare Conference: Nov. 29-Dec. 2 American Epilepsy Society, or AES, 2021 Annual Meeting: Dec. 3-7, in Full story available on Benzinga.com

Zacks Investment Research downgraded shares of VBI Vaccines (NASDAQ:VBIV) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports. According to Zacks, VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The companys eVLP vaccine platform allows for the design []

VBI Vaccines Inc. (NASDAQ:VBIV) Analysts at Jefferies Financial Group increased their FY2021 EPS estimates for shares of VBI Vaccines in a report issued on Thursday, November 18th. Jefferies Financial Group analyst K. Chikere now anticipates that the biopharmaceutical company will post earnings of ($0.27) per share for the year, up from their previous estimate []

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 25.00% and -58.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock

VBI Vaccines will find out on November 30th whether its Hepatitis B vaccine - already approved in Israel - will be approved by the FDA in the US. Approval in the US - and Europe, where a marketing aut

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on Investor

Which penny stocks are on your watchlist this month? The post Best Penny Stocks to Buy in September 2021?

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 12.50% and -73.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today report

My coverage of VBI Vaccines has been overly focused on the company's infectious disease programs and I have discounted the company's glioblastoma candidate, VBI-1901. The company presented impressive

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today report

Investors almost seemed ready to take profits once shares hit their highest level since February.

VBI Vaccines Inc (NASDAQ: VBIV) has announced positive Phase 1 data from its Phase 1/2 trial evaluating its enveloped virus-like particle (eVLP) COVID-19 vaccine candidate VBI-2902a. VBI-2902a was